Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today provided corporate updates and reported financial results for the second quarter ended June 30, 2022.
“We are excited by the advances we made this quarter related to our lead program in recurrent C. difficile infection, including significant progress on a number of activities that we expect will position us to proceed with enrollment in our PRISM4 Phase 3 trial of CP101 later this year. We are also pleased to be presenting microbiome data from our PRISM-EXT Phase 2 open-label trial of CP101 in recurrent C. difficile at ACG 2022,” said Mark Smith, PhD, Chief Executive Officer of Finch Therapeutics.
Dr. Smith continued, “Additionally, we are preparing to submit the IND for FIN-211 in children with autism and significant GI symptoms, with the submission anticipated later this year. We look forward to continuing to advance our mission to harness the microbiome to transform outcomes for people impacted by conditions linked to microbiome disruption.”
Recent Program Highlights
CP101 for Prevention of Recurrent C. difficile Infection (CDI):
FIN-211 for Autism Spectrum Disorder (ASD) with Significant Gastrointestinal (GI) Symptoms:
Second Quarter 2022 Financial Results
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is also developing FIN-211 for children with autism spectrum disorder and significant gastrointestinal symptoms. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease. Finch routinely posts information that may be important to its investors on its website at www.finchtherapeutics.com. Finch encourages investors to consult the “Investors & News” section of its website regularly.
Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.
Forward-Looking Statements
This press release includes “forward-looking statements.” Words such as “will,” "anticipates," "believes," "expects," "intends," “plans,” “potential,” "projects,” “would” and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding: Finch’s ability to advance its mission; Finch’s ability to complete activities that it expects will position it to proceed with enrollment in PRISM4 later this year; Finch’s plans to advance FIN-211 into the clinic; the timeline for topline data from PRISM4 and plans to present translational data from PRISM-EXT; the timeline for submission of the IND for FIN-211; the design and anticipated enrollment in AUSPIRE; and Finch's anticipated runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the risk that correspondence from the FDA may require Finch to collect additional data or information beyond what it currently expects, as well as unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; uncertainties relating to regulatory applications and related filing and approval timelines; Finch’s limited operating history and historical losses; Finch’s ability to raise additional funding to complete the development and any commercialization of its product candidates; Finch’s dependence on the success of its lead product candidate, CP101; the possibility that Finch may be delayed in initiating, enrolling or completing any clinical trials; results of clinical trials may not be indicative of final or future results from later stage or larger clinical trials (or in broader patient populations once the product is approved for use by regulatory agencies) or may not be favorable or may not support further development; Finch’s product candidates, including CP101 and FIN-211 may not generate the benefits to patients that are anticipated; results of clinical trials may not be sufficient to satisfy regulatory authorities to approve Finch’s product candidates in their targeted or other indications (or such authorities may request additional trials or additional information); Finch’s ability to comply with regulatory requirements; ongoing regulatory obligations and continued regulatory review may result in significant additional expense to Finch and Finch may be subject to penalties for failure to comply; competition from third parties that are developing products for similar uses; Finch’s ability to maintain patent and other intellectual property protection and the possibility that Finch’s intellectual property rights may be infringed, invalid or unenforceable or will be threatened by third parties; Finch’s ability to qualify and scale its manufacturing capabilities in anticipation of commencement of multiple global clinical trials; Finch’s lack of experience in selling, marketing and distributing its product candidates; Finch’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and risks relating to the impact and duration of the COVID-19 pandemic on Finch’s business. These and other risks are described more fully in Finch’s filings with the Securities and Exchange Commission (“SEC”), including the section titled “Risk Factors” in Finch’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 31, 2022, as supplemented by Finch’s Quarterly Report on Form 10-Q filed with the SEC on May 16, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Finch’s other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Finch undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525-2047
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Jenna Urban
Berry & Company Public Relations
(212) 253-8881
This email address is being protected from spambots. You need JavaScript enabled to view it.
Finch Therapeutics Group, Inc.
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except share and per share data)
FOR THE THREE MONTHS ENDED JUNE 30, | FOR THE SIX MONTHS ENDED JUNE 30, | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Revenue: | ||||||||||||||||
Collaboration revenue | $ | 361 | $ | 2,830 | $ | 715 | $ | 6,383 | ||||||||
Total revenue | 361 | 2,830 | 715 | 6,383 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 13,923 | 13,964 | 29,453 | 26,939 | ||||||||||||
General and administrative | 8,164 | 5,882 | 17,568 | 10,433 | ||||||||||||
Restructuring expense | 903 | - | 903 | - | ||||||||||||
Total operating expenses | 22,990 | 19,846 | 47,924 | 37,372 | ||||||||||||
Loss from operations | (22,629 | ) | (17,016 | ) | (47,209 | ) | (30,989 | ) | ||||||||
Other (expense) income | (71 | ) | 1,847 | (58 | ) | 1,839 | ||||||||||
Net loss | $ | (22,700 | ) | $ | (15,169 | ) | $ | (47,267 | ) | $ | (29,150 | ) | ||||
Net loss per share attributable to common stockholders—basic and diluted | $ | (0.48 | ) | $ | (0.32 | ) | $ | (0.99 | ) | $ | (0.95 | ) | ||||
Weighted-average common stock outstanding—basic and diluted | 47,576,349 | 47,379,887 | 47,552,780 | 30,798,698 |
Finch Therapeutics Group, Inc.
Condensed Consolidated Balance Sheet Data (Unaudited)
(in thousands)
JUNE 30, 2022 | DECEMBER 31, 2021 | |||||||
Assets: | ||||||||
Cash and cash equivalents | $ | 104,673 | $ | 133,481 | ||||
Other assets | 123,628 | 91,888 | ||||||
Total assets | $ | 228,301 | $ | 225,369 | ||||
Liabilities, redeemable convertible preferred stock and stockholders' equity | ||||||||
Liabilities | 69,209 | 23,145 | ||||||
Stockholders' equity | 159,092 | 202,224 | ||||||
Total liabilities, redeemable convertible preferred stock and stockholders' equity | $ | 228,301 | $ | 225,369 |
Last Trade: | US$11.69 |
Daily Change: | 9.89 549.44 |
Daily Volume: | 5,850 |
Market Cap: | US$18.820M |
May 10, 2023 March 23, 2023 November 10, 2022 September 01, 2022 |
Surf Air Mobility is a regional air mobility platform expanding the category of regional air travel to reinvent flying through the power of electrification. In an effort to substantially reduce the cost and environmental impact of...
CLICK TO LEARN MOREHillcrest Energy Technologies is a clean technology company developing high value, high performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable...
CLICK TO LEARN MORECOPYRIGHT ©2022 GREEN STOCK NEWS